Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Percy

Showing results (171-180 of 227) with videos related to

Pageof 23
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 4, 2008
A phase I study of 17-allylamino-17-demethoxygeldanamycin combined with paclitaxel in patients with advanced solid malignanciesSuresh S Ramalingam, Merrill J Egorin, Ramesh K Ramanathan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 17, 2007
Phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancerDavid B Solit, S Percy Ivy, Catherine Kopil, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 17, 2007
A phase I study of 17-allylaminogeldanamycin in relapsed/refractory pediatric patients with solid tumors: a Children's Oncology Group studyBrenda J Weigel, Susan M Blaney, Joel M Reid, et al.
Journal of the National Cancer Institute|March 31, 2010
Initial assessment, surveillance, and management of blood pressure in patients receiving vascular endothelial growth factor signaling pathway inhibitorsMichael L Maitland, George L Bakris, Henry R Black, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|October 14, 2024
Characterization of the Biological Variability of the Angiome Biomarkers over Time in Healthy ParticipantsYingmiao Liu, Jiatong Li, Jing Lyu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 17, 2007
Phase I and pharmacodynamic study of 17-(allylamino)-17-demethoxygeldanamycin in adult patients with refractory advanced cancersRamesh K Ramanathan, Merrill J Egorin, Julie L Eiseman, et al.
International Journal of Radiation Oncology, Biology, Physics|July 24, 2012
A dose escalation and pharmacodynamic study of triapine and radiation in patients with locally advanced pancreas cancerLudmila Katherine Martin, John Grecula, Guang Jia, et al.
The Oncologist|June 2, 2019
Phase II, Multicenter, Randomized Trial of Docetaxel plus Prednisone with or Without Cediranib in Men with Chemotherapy-Naive Metastatic Castrate-Resistant Prostate CancerElisabeth Heath, Lance Heilbrun, Heather Mannuel, et al.
Cancer Chemotherapy and Pharmacology|November 30, 2011
A phase I trial of docetaxel and pulse-dose 17-allylamino-17-demethoxygeldanamycin in adult patients with solid tumorsGopa Iyer, Michael J Morris, Dana Rathkopf, et al.
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada|January 2, 2015
Evaluation of second-line and subsequent targeted therapies in metastatic renal cell cancer (mRCC) patients treated with first-line cediranibSuzanne Richter, Jo-An Seah, Gregory R Pond, et al.
Pageof 23

Showing results (171-180 of 227) with videos related to

Sort By:
Pageof 23
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 4, 2008
A phase I study of 17-allylamino-17-demethoxygeldanamycin combined with paclitaxel in patients with advanced solid malignanciesSuresh S Ramalingam, Merrill J Egorin, Ramesh K Ramanathan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 17, 2007
Phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancerDavid B Solit, S Percy Ivy, Catherine Kopil, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 17, 2007
A phase I study of 17-allylaminogeldanamycin in relapsed/refractory pediatric patients with solid tumors: a Children's Oncology Group studyBrenda J Weigel, Susan M Blaney, Joel M Reid, et al.
Journal of the National Cancer Institute|March 31, 2010
Initial assessment, surveillance, and management of blood pressure in patients receiving vascular endothelial growth factor signaling pathway inhibitorsMichael L Maitland, George L Bakris, Henry R Black, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|October 14, 2024
Characterization of the Biological Variability of the Angiome Biomarkers over Time in Healthy ParticipantsYingmiao Liu, Jiatong Li, Jing Lyu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 17, 2007
Phase I and pharmacodynamic study of 17-(allylamino)-17-demethoxygeldanamycin in adult patients with refractory advanced cancersRamesh K Ramanathan, Merrill J Egorin, Julie L Eiseman, et al.
International Journal of Radiation Oncology, Biology, Physics|July 24, 2012
A dose escalation and pharmacodynamic study of triapine and radiation in patients with locally advanced pancreas cancerLudmila Katherine Martin, John Grecula, Guang Jia, et al.
The Oncologist|June 2, 2019
Phase II, Multicenter, Randomized Trial of Docetaxel plus Prednisone with or Without Cediranib in Men with Chemotherapy-Naive Metastatic Castrate-Resistant Prostate CancerElisabeth Heath, Lance Heilbrun, Heather Mannuel, et al.
Cancer Chemotherapy and Pharmacology|November 30, 2011
A phase I trial of docetaxel and pulse-dose 17-allylamino-17-demethoxygeldanamycin in adult patients with solid tumorsGopa Iyer, Michael J Morris, Dana Rathkopf, et al.
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada|January 2, 2015
Evaluation of second-line and subsequent targeted therapies in metastatic renal cell cancer (mRCC) patients treated with first-line cediranibSuzanne Richter, Jo-An Seah, Gregory R Pond, et al.
Pageof 23